TD2 Oncology, Minerva Imaging team up on radiopharmaceutical trials

TD2 Oncology and Minerva Imaging announced a partnership on July 22, 2026, to streamline radiopharmaceutical programs from translational work into first-in-human and early-phase studies. The collaboration combines TD2’s clinical and regulatory expertise with Minerva’s imaging, radiochemistry and CDMO capabilities to help sponsors move faster with less development risk.

Why it matters: - Radiopharmaceutical programs often stall when radiochemistry, CMC planning, imaging strategy, regulatory work, drug supply and trial execution sit with separate vendors. - The partnership is designed to give sponsors a more coordinated path from discovery and translational research into first-in-human and early-phase clinical studies. - Faster clinic entry can matter for radioligand therapy developers trying to reduce delay without compromising quality or compliance.

What happened: - TD2 Oncology announced a partnership with Minerva Imaging on July 22, 2026. - TD2 Oncology is an oncology-focused CRO specializing in translational, regulatory and clinical drug development. - Minerva Imaging is a CRO and CDMO focused on targeted radiopharmaceutical development, molecular imaging and manufacturing. - The collaboration expands TD2’s radioligand therapy capabilities. - The partnership is active now and available to sponsors.

The details: - TD2 is contributing oncology clinical development, regulatory strategy, medical oversight, site engagement and early-phase trial execution. - Minerva is contributing radiopharmaceutical CDMO services, imaging strategy, radiochemistry development and clinical dose supply. - The companies say the combined model covers the core requirements needed to advance radioligand therapy programs from discovery to clinical trials. - The announcement says the goal is to integrate activities that are often split across multiple teams and vendors. - TD2 and Minerva say the integrated approach is meant to support seamless progress into first-in-human and early-phase studies. - Stephen Gately, CEO of TD2 Oncology, said radiopharmaceutical programs require a highly specialized, multidisciplinary team to move quickly while identifying and mitigating development risks. - Gately said the partnership is part of TD2’s long-term commitment to companies and patients in the radioligand therapy space. - Carsten Haagen Nielsen, CEO of Minerva Imaging, said sponsors need a partner that can move at the pace of the science without compromising quality or compliance. - Nielsen said the companies aim to provide a single, coordinated path from translational research to first patients dosed in the U.S. - Minerva Imaging was founded in Denmark in 2011. - Minerva works with pharmaceutical and biotech partners on radiopharmaceutical and theranostic programs from early development through clinical supply. - TD2 Oncology helps biopharma partners advance cancer therapies through preclinical studies, translational strategy, regulatory development and clinical execution. - The announcement includes a LinkedIn link for TD2 Oncology: TD2 Oncology on LinkedIn. - More information is available from Minerva Imaging at the company’s website. - More information is available from TD2 Oncology at the company’s website.

Between the lines: - The partnership reflects a broader push in radiopharmaceutical development to reduce handoffs between specialized vendors. - A combined CRO/CDMO model can help sponsors align scientific, manufacturing and clinical steps earlier in development. - The U.S.-focused coordination language suggests both companies want to make cross-functional trial startup simpler for sponsors entering the clinic.

What's next: - Sponsors can now seek integrated support from TD2 and Minerva for translational strategy, first-in-human trials and other early-phase studies. - The companies will likely use the partnership to position themselves as a single entry point for radioligand therapy developers needing both clinical and manufacturing support. - The announcement does not disclose specific programs, customers or financial terms.